{"entity":{"id":"nct05276310","kind":"trial","name":"A Study of IMC-002 in Patients With Advanced Cancer Failed to Standard Therapy","aka":[],"tldr":"A phase 1 trial of IMC-002 run by ImmuneOncia Therapeutics Inc., now recruiting.","summary":"A Study of IMC-002 in Patients With Advanced Cancer Failed to Standard Therapy is a phase 1 interventional study registered as NCT05276310 by ImmuneOncia Therapeutics Inc., with 86 participants planned, started 2022-06-02. Conditions recorded: Advanced Cancer. Interventions recorded: IMC-002.","status":"recruiting","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT05276310","url":"https://clinicaltrials.gov/study/NCT05276310"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["imc-002"],"companies":["immuneoncia-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05276310","phase":"1","setting":"An Open-Label, Dose-Escalation and Expansion, Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of IMC-002 in Patients With Advanced Cancer Failed to Standard Therapy","sponsor":"ImmuneOncia Therapeutics Inc.","enrolled":86,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05276310/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"imc-002","kind":"drug","name":"IMC-002","route":"/drugs/imc-002/"}],"company":[{"id":"immuneoncia-therapeutics","kind":"company","name":"ImmuneOncia Therapeutics","route":"/companies/immuneoncia-therapeutics/"}]}}